Research Analysts Offer Predictions for SLN Q3 Earnings

Key Points

• William Blair has revised its Q3 2025 earnings per share (EPS) estimate for Silence Therapeutics PLC from ($0.38) to ($0.39), indicating a continued negative outlook for the company's financial performance.
• The firm's most recent earnings report showed Silence Therapeutics missed consensus estimates with a reported EPS of ($0.54) for the quarter, against an expected ($0.27).
• Despite the pessimistic forecast, the current consensus rating for Silence Therapeutics is a "Moderate Buy", with an average target price of $33.83, according to MarketBeat.com.

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Free Report) - William Blair lowered their Q3 2025 earnings estimates for shares of Silence Therapeutics in a report issued on Thursday, August 7th. William Blair analyst M. Minter now anticipates that the company will earn ($0.39) per share for the quarter, down from their prior forecast of ($0.38). The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for Silence Therapeutics' Q4 2025 earnings at ($0.30) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($0.91) EPS.

A number of other analysts also recently weighed in on the stock. Morgan Stanley cut their price target on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Chardan Capital restated a "buy" rating and set a $35.00 target price on shares of Silence Therapeutics in a report on Friday, August 8th. Wall Street Zen downgraded shares of Silence Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, July 12th. HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, June 13th. Finally, The Goldman Sachs Group dropped their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat, Silence Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $33.83.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN traded down $0.24 during mid-day trading on Monday, hitting $5.62. The company's stock had a trading volume of 19,247 shares, compared to its average volume of 208,893. The stock has a market cap of $168.06 million, a price-to-earnings ratio of -3.40 and a beta of 1.39. Silence Therapeutics has a one year low of $1.97 and a one year high of $20.48. The company's fifty day simple moving average is $5.81 and its 200-day simple moving average is $4.71.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.27). The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $8.50 million. Silence Therapeutics had a negative net margin of 294.20% and a negative return on equity of 67.48%.

Institutional Trading of Silence Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $26,000. Barclays PLC grew its stake in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after buying an additional 2,793 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Silence Therapeutics by 134.1% in the second quarter. GAMMA Investing LLC now owns 8,333 shares of the company's stock valued at $48,000 after buying an additional 4,773 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after buying an additional 6,098 shares in the last quarter. Finally, Beacon Pointe Advisors LLC bought a new position in shares of Silence Therapeutics in the second quarter valued at $67,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.